Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moREVEFENACIN (revefenacin) by Viatris (2) is long-acting muscarinic antagonist, which is often referred to as an anticholinergic.
Drug data last refreshed 1mo ago
long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Revefenacin in Acute Respiratory Insufficiency in COPD
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
Worked on REVEFENACIN at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo